FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311746729> ?p ?o ?g. }

• W4311746729 abstract "Abstract Background ESBL-producing E. coli (ESBLEC) continues to increase worldwide. For the infection due to ESBLEC, no antimicrobial agent has clearly demonstrated therapeutic effectiveness comparable to that of carbapenem. Overuse of carbapenems may lead to an increase in carbapenem-resistant bacteria. Cefmetazole (CMZ) is active against ESBLEC, however, there are limited multicenter studies on the effectiveness of CMZ, an important carbapenem-sparing therapy for the treatment of ESBLEC. Methods This prospective, observational study included patients hospitalized for invasive urinary tract infection (iUTI) due to ESBLEC between March 2020 and November 2021 at 10 centers in Japan, with either CMZ or meropenem (MEM) initiated within 96 hours of culture submission as definitive therapy, and used for at least 4 days. The diagnosis of iUTI was made in patients with a fever of ≥37.5°C, symptom of pyelonephritis such as back pain, pyuria, and ESBLEC detected in urine (≥10^4 CFU/mL). Outcomes included clinical effectiveness (resolution of all clinical symptoms or improvement to pre-infection status) between day 4 to 6 of treatment (early) and between the final day of treatment and 2 days later (late), microbiological effectiveness (reduction to ≤10^3 CFU/ml) between day 4 to 6, and mortality. Outcomes were adjusted for the inverse probability of propensity scores (PS) for receiving CMZ or MEM treatment. Results Seventy-seven patients in the CMZ group and 46 in the MEM group were included. In univariate analysis, the CMZ group was older than the MEM group, although the MEM group had higher qSOFA, CRP, more frequent medical device use and concurrent bacteremia at the start of study drugs than the CMZ group (Table). Univariate analysis showed no difference in clinical effectiveness, and 30-day mortality was higher in the MEM group. In all cases with available data (CMZ: n=57, MEM: n=22), both drugs were microbiologically effective. After PS adjustment, clinical effectiveness did not differ between the two groups. The risk of 30-day mortality was lower in CMZ group, whereas the risk of recurrence was similar in both groups. Conclusion CMZ is as effective as MEM for the treatment of iUTI, suggesting that it is a promising carbapenem-sparing therapy. Disclosures Sho Saito, MD, PhD, DAIICHI SANKYO: Grant/Research Support|EVEC: Grant/Research Support|EVEC: Patents obtained through collaborative research|SHIONOGI: Grant/Research Support|Takeda: Advisor/Consultant." @default.
• W4311746729 created "2022-12-28" @default.
• W4311746729 creator A5002303307 @default.
• W4311746729 creator A5004871899 @default.
• W4311746729 creator A5006534529 @default.
• W4311746729 creator A5007757700 @default.
• W4311746729 creator A5008639301 @default.
• W4311746729 creator A5022751311 @default.
• W4311746729 creator A5025336363 @default.
• W4311746729 creator A5043849320 @default.
• W4311746729 creator A5051481287 @default.
• W4311746729 creator A5058736163 @default.
• W4311746729 creator A5079221259 @default.
• W4311746729 creator A5079585400 @default.
• W4311746729 creator A5081203939 @default.
• W4311746729 creator A5085225502 @default.
• W4311746729 creator A5088044766 @default.
• W4311746729 date "2022-12-01" @default.
• W4311746729 modified "2023-10-14" @default.
• W4311746729 title "658. Evaluation of Effectiveness of Cefmetazole vs Meropenem for Invasive Urinary Tract Infections Caused by ESBL-Producing <i>Escherichia coli</i>: A Prospective Multicenter Observational Study" @default.
• W4311746729 doi "https://doi.org/10.1093/ofid/ofac492.710" @default.
• W4311746729 hasPublicationYear "2022" @default.
• W4311746729 type Work @default.
• W4311746729 citedByCount "0" @default.
• W4311746729 crossrefType "journal-article" @default.
• W4311746729 hasAuthorship W4311746729A5002303307 @default.
• W4311746729 hasAuthorship W4311746729A5004871899 @default.
• W4311746729 hasAuthorship W4311746729A5006534529 @default.
• W4311746729 hasAuthorship W4311746729A5007757700 @default.
• W4311746729 hasAuthorship W4311746729A5008639301 @default.
• W4311746729 hasAuthorship W4311746729A5022751311 @default.
• W4311746729 hasAuthorship W4311746729A5025336363 @default.
• W4311746729 hasAuthorship W4311746729A5043849320 @default.
• W4311746729 hasAuthorship W4311746729A5051481287 @default.
• W4311746729 hasAuthorship W4311746729A5058736163 @default.
• W4311746729 hasAuthorship W4311746729A5079221259 @default.
• W4311746729 hasAuthorship W4311746729A5079585400 @default.
• W4311746729 hasAuthorship W4311746729A5081203939 @default.
• W4311746729 hasAuthorship W4311746729A5085225502 @default.
• W4311746729 hasAuthorship W4311746729A5088044766 @default.
• W4311746729 hasBestOaLocation W43117467291 @default.
• W4311746729 hasConcept C126322002 @default.
• W4311746729 hasConcept C141071460 @default.
• W4311746729 hasConcept C188816634 @default.
• W4311746729 hasConcept C23131810 @default.
• W4311746729 hasConcept C2775886723 @default.
• W4311746729 hasConcept C2776237055 @default.
• W4311746729 hasConcept C2776520383 @default.
• W4311746729 hasConcept C2776685102 @default.
• W4311746729 hasConcept C2779375183 @default.
• W4311746729 hasConcept C501593827 @default.
• W4311746729 hasConcept C64778159 @default.
• W4311746729 hasConcept C71924100 @default.
• W4311746729 hasConcept C77411442 @default.
• W4311746729 hasConcept C86803240 @default.
• W4311746729 hasConcept C89423630 @default.
• W4311746729 hasConcept C94665300 @default.
• W4311746729 hasConceptScore W4311746729C126322002 @default.
• W4311746729 hasConceptScore W4311746729C141071460 @default.
• W4311746729 hasConceptScore W4311746729C188816634 @default.
• W4311746729 hasConceptScore W4311746729C23131810 @default.
• W4311746729 hasConceptScore W4311746729C2775886723 @default.
• W4311746729 hasConceptScore W4311746729C2776237055 @default.
• W4311746729 hasConceptScore W4311746729C2776520383 @default.
• W4311746729 hasConceptScore W4311746729C2776685102 @default.
• W4311746729 hasConceptScore W4311746729C2779375183 @default.
• W4311746729 hasConceptScore W4311746729C501593827 @default.
• W4311746729 hasConceptScore W4311746729C64778159 @default.
• W4311746729 hasConceptScore W4311746729C71924100 @default.
• W4311746729 hasConceptScore W4311746729C77411442 @default.
• W4311746729 hasConceptScore W4311746729C86803240 @default.
• W4311746729 hasConceptScore W4311746729C89423630 @default.
• W4311746729 hasConceptScore W4311746729C94665300 @default.
• W4311746729 hasIssue "Supplement_2" @default.
• W4311746729 hasLocation W43117467291 @default.
• W4311746729 hasLocation W43117467292 @default.
• W4311746729 hasOpenAccess W4311746729 @default.
• W4311746729 hasPrimaryLocation W43117467291 @default.
• W4311746729 hasRelatedWork W1982211555 @default.
• W4311746729 hasRelatedWork W2114808773 @default.
• W4311746729 hasRelatedWork W2474245941 @default.
• W4311746729 hasRelatedWork W2770750156 @default.
• W4311746729 hasRelatedWork W2801265347 @default.
• W4311746729 hasRelatedWork W2911389279 @default.
• W4311746729 hasRelatedWork W2967682777 @default.
• W4311746729 hasRelatedWork W3137961730 @default.
• W4311746729 hasRelatedWork W4311746729 @default.
• W4311746729 hasRelatedWork W51355695 @default.
• W4311746729 hasVolume "9" @default.
• W4311746729 isParatext "false" @default.
• W4311746729 isRetracted "false" @default.
• W4311746729 workType "article" @default.